Export
Model List of Essential Medicines
Found 1312 recommendations for 635 medicines and 135 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
-
BCG vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Japanese encephalitis vaccine General information
SectionRecommendations for certain regions- All vaccines should comply with the WHO requirements for biological substances.
-
Medicines for COVID-19 General information
SectionMedicines for COVID-19- Refer to WHO living guidelines
Indications -
Abacavir General information
SectionAntiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Solid: 300 mg tablet (as sulfate)
-
Abacavir + lamivudine General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
-
Abiraterone General information
SectionHormones and antihormones- Oral > Solid: 250 mg; 500 mg
Indications -
Acamprosate calcium General information
SectionMedicines for alcohol use disorders- Oral > Solid > tablet: 333 mg
Indications -
Acetazolamide General information
SectionOphthalmological preparations > Miotics and antiglaucoma medicines- Oral > Solid: 250 mg
Indications -
Acetic acid General information
SectionEar, nose and throat medicines [c]- Local > Otological > drops: 2% in alcohol
Indications -
Acetylcysteine General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
- Oral > Liquid: 10%; 20%
-
Acetylsalicylic acid General information
SectionAntimigraine medicines > For treatment of acute attack- Oral > Solid: 300 to 500 mg
IndicationsSectionAnti-platelet medicines- Oral > Solid: 100 mg
IndicationsSectionMedicines for juvenile joint diseases- Oral > Solid: 100 to 500 mg
- Local > Rectal > Suppository: 50 to 150 mg
SectionNon-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)- Oral > Solid: 100 to 500 mg
- Local > Rectal > Suppository: 50 to 150 mg
Indications -
Acetylsalicylic acid + atorvastatin + ramipril General information
SectionFixed-dose combinations for prevention of atherosclerotic cardiovascular disease- Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg
-
Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide General information
SectionFixed-dose combinations for prevention of atherosclerotic cardiovascular disease- Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg
-
Aciclovir General information
SectionAntiherpes medicines- Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
- Oral > Liquid: 200 mg per 5 mL
- Oral > Solid: 200 mg tablet
IndicationsSectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Ointment: 3% w/w
Indications -
Aclidinium General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease -
Activated charcoal General information
SectionAntidotes and other substances used in poisonings > Non-specific- Oral > Other: powder
-
Adalimumab General information
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
SectionMedicines for juvenile joint diseases- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
Indications -
Afatinib General information
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung -
Albendazole General information
SectionIntestinal anthelminthics- Oral > Solid > tablet: 400 mg (chewable, scored)
SectionCysticidal medicines- Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)
SectionAntifilarials- Oral > Solid > tablet: 400 mg (chewable, scored)
Indications -
Alcohol based hand rub General information
SectionDisinfectants- Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
Indications -
All-trans retinoic acid General information
SectionTargeted therapies- Oral > Solid: 10 mg capsule
-
Allopurinol General information
SectionMedicines used to treat gout- Oral > Solid: 100 mg
IndicationsSectionSupportive medicines- Oral > Solid: 100 mg; 300 mg
Indications -
Alteplase General information
SectionThrombolytic medicines- Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
Indications -
Amidotrizoate General information
SectionDiagnostic agents > Radiocontrast media- Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
Indications -
Amikacin General information
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitisSectionAntituberculosis medicines- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
IndicationsSectionAccess group antibiotics- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
IndicationsFirst choice
Neutropenia (high-risk) co-prescribed with cefotaxime Inflammatory and other diseases of prostate (severe) co-prescribed with cefotaxime Acute pyelonephritis (severe) co-prescribed with ceftriaxone Inflammatory and other diseases of prostate (severe) co-prescribed with ceftriaxone Acute pyelonephritis (severe)Second choice
co-prescribed with cloxacillin Sepsis without septic shock -
Amiloride General information
-
Amiodarone General information
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
Indications -
Amitriptyline General information
SectionMedicines for other common symptoms in palliative care- Oral > Solid: 25 mg; 10 mg; 75 mg
IndicationsSectionMedicines for depressive disorders- Oral > Solid: 25 mg; 75 mg
Indications -
Amlodipine General information
SectionAntihypertensive medicines- Oral > Solid: 5 mg (as maleate, mesylate or besylate)
Indications -
Amodiaquine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)
-
Amodiaquine + sulfadoxine + pyrimethamine General information
SectionAntimalarial medicines > For chemoprevention- Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package
Indications -
Amoxicillin General information
SectionAccess group antibiotics- Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
- Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
- Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)
- Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)
IndicationsFirst choice
Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Acute pharyngitis Chronic obstructive pulmonary disease with acute exacerbation Periapical abscess without sinus Acute otitis media Acute sinusitis co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with gentamicin Sepsis without septic shockSecond choice
Bacterial meningitis -
Amoxicillin + clavulanic acid General information
SectionAccess group antibiotics- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
IndicationsFirst choice
Peritoneal abscess (mild-moderate) Neutropenia (low-risk) Other specified pneumonia (Hospital-acquired pneumonia) Infectious cystitis Chronic obstructive pulmonary disease with acute exacerbation Peritonitis (mild-moderate) Acute sinusitis Bacterial cellulitis, erysipelas or lymphangitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children]SectionAntituberculosis medicines- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
Indications -
Amphotericin B General information
SectionAntifungal medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
SectionAntileishmaniasis medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)
Indications -
Ampicillin General information
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
IndicationsFirst choice
co-prescribed with gentamicin Peritoneal abscess (severe) co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Peritoneal abscess (mild-moderate) co-prescribed with gentamicin Peritonitis (severe) co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Peritonitis (mild-moderate) co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]Second choice
Bacterial meningitis -
Anastrozole General information
SectionHormones and antihormones- Oral > Solid: 1 mg tablet
-
Anidulafungin General information
SectionAntifungal medicinesIndicationsTherapeutic equivalent to micafungin for Systemic or invasive candidosis -
Ansuvimab General information
SectionMedicines for Ebola virus disease- Parenteral > General injections > IV: 400 mg powder for injection
Indications -
Anti-D immunoglobulin General information
SectionHuman immunoglobulins- Parenteral > General injections > IV: 250 µg in single-dose vial
- Parenteral > General injections > IM: 250 µg in single-dose vial
-
Anti-rabies immunoglobulin General information
SectionHuman immunoglobulins- Parenteral > General injections > IM: 150 IU per mL in vial
- Parenteral > Locoregional injections > Other: 150 IU per mL in vial
Indications -
Anti-rabies virus monoclonal antibodies General information
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
Indications -
Anti-tetanus immunoglobulin General information
SectionHuman immunoglobulins- Parenteral > General injections > IM: 500 IU in vial
Indications -
Antivenom immunoglobulin General information
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > General injections > IV:
-
Apixaban General information
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation -
Aprepitant General information
SectionAntiemetic medicines- Oral > Liquid: 125 mg powder for oral suspension (in sachet)
- Oral > Solid: 80 mg; 125 mg; 165 mg
Indications -
Aripiprazole General information
SectionMedicines for psychotic disordersIndicationsTherapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders -
Arsenic trioxide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
-
Artemether General information
SectionAntimalarial medicines > For curative treatment- Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)
-
Artemether + lumefantrine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet
-
Artesunate General information
SectionAntimalarial medicines > For curative treatment- Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
- Oral > Solid: 50 mg tablet
- Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules
-
Artesunate + amodiaquine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet
-
Artesunate + mefloquine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet
-
Artesunate + pyronaridine tetraphosphate General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules
-
Ascorbic acid General information
SectionVitamins and minerals- Oral > Solid: 50 mg
Indications -
Asparaginase General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
Indications -
Atazanavir + ritonavir General information
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
-
Atenolol General information
SectionAntihypertensive medicinesIndicationsTherapeutic equivalent to bisoprolol for Essential hypertension -
Atoltivimab + maftivimab + odesivimab General information
SectionMedicines for Ebola virus disease- Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial
Indications -
Atorvastatin General information
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis -
Atorvastatin + perindopril + amlodipine General information
SectionFixed-dose combinations for prevention of atherosclerotic cardiovascular disease- Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg
-
Atracurium General information
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Parenteral > General injections > IV: 10 mg per mL (besylate)
Indications -
Atropine General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
SectionPreoperative medication and sedation for short-term procedures- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
SectionDiagnostic agents > Ophthalmic medicinesIndicationsTherapeutic equivalent to tropicamide for Cycloplegic drugSectionOphthalmological preparations > Mydriatics- Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
Indications -
Azathioprine General information
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)
- Oral > Liquid: 10 mg per mL
- Oral > Solid > tablet: 25 mg; 50 mg (scored)
SectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid > tablet: 50 mg (scored)
-
Azithromycin General information
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
IndicationsSectionWatch group antibiotics- Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)
IndicationsFirst choice
Chlamydia trachomatis Typhoid fever Yaws Paratyphoid fever Cholera Cholera [children] Trachoma co-prescribed with ceftriaxone Gonococcal infectionSecond choice
Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with cefixime Gonococcal infection -
Barium sulfate General information
SectionDiagnostic agents > Radiocontrast media- Oral > Liquid: Aqueous suspension
Indications -
Beclometasone General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide for Asthma -
Beclometasone + formoterol General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol for Asthma -
Bedaquiline General information
SectionAntituberculosis medicines- Oral > Solid: 100 mg tablet; 20 mg tablet
Indications -
Bendamustine General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
-
Benzathine benzylpenicillin General information
SectionAccess group antibiotics- Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection
-
Benznidazole General information
SectionAmerican trypanosomiasis- Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg
Indications -
Benzoyl peroxide General information
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Cream: 5%
- Local > Topical > Lotion: 5%
Indications -
Benzyl benzoate General information
SectionDermatological medicines > Scabicides and pediculicides- Local > Topical > Lotion: 25%
Indications -
Benzylpenicillin General information
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
IndicationsFirst choice
Congenital syphilis [children] Syphilis co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]Second choice
Bacterial meningitis -
Betamethasone General information
SectionDermatological medicines > Anti-inflammatory and antipruritic medicines- Local > Topical > Cream: 0.1% (as valerate)
- Local > Topical > Ointment: 0.1% (as valerate)
-
Bevacizumab General information
SectionOphthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations- Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
Indications -
Bicalutamide General information
SectionHormones and antihormones- Oral > Solid: 50 mg
Indications -
Biperiden General information
SectionMedicines for parkinsonism- Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
- Oral > Solid: 2 mg tablet (hydrochloride)
Indications -
Bisacodyl General information
SectionLaxativesIndicationsTherapeutic equivalent to senna for Constipation -
Bisoprolol General information
SectionAntianginal medicines- Oral > Solid: 1.25 mg; 5 mg
IndicationsSectionMedicines used in heart failure- Oral > Solid: 1.25 mg; 5 mg
IndicationsSectionAntihypertensive medicines- Oral > Solid: 1.25 mg; 5 mg
IndicationsSectionAntiarrhythmic medicines- Oral > Solid: 1.25 mg; 5 mg
Indications -
Bleomycin General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)
-
Bortezomib General information
SectionTargeted therapies- Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
Indications -
Bromocriptine General information
SectionMedicines for disorders of the pituitary hormone systemIndicationsTherapeutic equivalent to cabergoline for Other specified benign neoplasm of endocrine glands -
Budesonide General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose
IndicationsSectionEar, nose and throat medicines [c]- Local > Nasal > Spray: 100 µg per dose
Indications -
Budesonide + formoterol General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose
Indications -
Budesonide + salmeterol General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol for Asthma -
Bumetanide General information
SectionMedicines used in heart failureIndicationsTherapeutic equivalent to furosemide for Heart failureSectionDiureticsIndicationsTherapeutic equivalent to furosemide for Anuria or oliguria Therapeutic equivalent to furosemide for Oedema -
Bupivacaine General information
SectionLocal anaesthetics- Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
- Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)
Indications -
Buprenorphine General information
SectionMedicines for opioid use disordersIndicationsTherapeutic equivalent to methadone for Opioid dependence -
Bupropion General information
SectionMedicines for nicotine use disorders- Oral > Solid: 150 mg sustained-release (hydrochloride)
Indications -
Cabergoline General information
SectionMedicines for disorders of the pituitary hormone system- Oral > Solid > tablet: 0.5 mg; 1 mg
-
Caffeine citrate General information
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
- Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
Indications -
Calamine General information
SectionDermatological medicines > Anti-inflammatory and antipruritic medicines- Local > Topical > Lotion:
Indications -
Calcipotriol General information
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Cream: 50 µg per mL (0.005%)
- Local > Topical > Lotion: 50 µg per mL (0.005%)
- Local > Topical > Ointment: 50 µg per mL (0.005%)
Indications -
Calcitriol General information
SectionDermatological medicines > Medicines affecting skin differentiation and proliferationIndicationsTherapeutic equivalent to calcipotriol for Psoriasis of unspecified type -
Calcium General information
SectionVitamins and minerals- Oral > Solid: 500 mg (elemental calcium)
Indications -
Calcium folinate (leucovorin calcium) General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
-
Calcium gluconate General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
IndicationsSectionVitamins and minerals- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
Indications -
Canagliflozin General information
SectionOral hypoglycaemic agentsIndicationsTherapeutic equivalent to empagliflozin for Type 2 diabetes mellitus -
Capecitabine General information
SectionCytotoxic medicines- Oral > Solid > tablet: 150 mg; 500 mg
-
Carbachol General information
SectionOphthalmological preparations > Miotics and antiglaucoma medicinesIndicationsTherapeutic equivalent to pilocarpine for Acute angle closure with pupillary block Therapeutic equivalent to pilocarpine for Ocular hypertension Therapeutic equivalent to pilocarpine for Primary open-angle glaucoma -
Carbamazepine General information
SectionMedicines for bipolar disorders- Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg
IndicationsSectionAntiseizure medicines- Oral > Liquid: 100 mg per 5 mL
- Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)
Indications -
Carbetocin General information
SectionUterotonics- Parenteral > General injections > IV: 100 µg per mL (heat stable)
Indications -
Carbimazole General information
SectionThyroid hormones and antithyroid medicinesIndicationsTherapeutic equivalent to methimazole for Thyrotoxicosis -
Carboplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL
IndicationsOther specified gliomas of brain Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Germ cell tumour of testis -
Carvedilol General information
SectionAntianginal medicinesIndicationsTherapeutic equivalent to bisoprolol for Angina pectorisSectionMedicines used in heart failureIndicationsTherapeutic equivalent to bisoprolol for Heart failureSectionAntihypertensive medicinesIndicationsTherapeutic equivalent to bisoprolol for Essential hypertensionSectionAntiarrhythmic medicinesIndicationsTherapeutic equivalent to bisoprolol for Cardiac arrhythmia -
Caspofungin General information
SectionAntifungal medicinesIndicationsTherapeutic equivalent to micafungin for Systemic or invasive candidosis -
Cefalexin General information
SectionAccess group antibiotics- Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
- Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
- Oral > Solid > dispersible tablet: 125 mg; 250 mg
-
Cefazolin General information
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
IndicationsFirst choice
Other specified prophylactic measures co-prescribed with metronidazole Other specified prophylactic measures -
Cefiderocol General information
SectionReserve group antibiotics- Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection
-
Cefixime General information
SectionWatch group antibiotics- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
IndicationsSecond choice
Infectious gastroenteritis or colitis without specification of infectious agent co-prescribed with azithromycin Gonococcal infection -
Cefotaxime General information
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
IndicationsFirst choice
Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with metronidazole Peritonitis (severe) co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate) -
Ceftazidime General information
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
-
Ceftazidime + avibactam General information
SectionReserve group antibiotics- Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
-
Ceftolozane + tazobactam General information
SectionReserve group antibiotics- Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
Indications -
Ceftriaxone General information
SectionWatch group antibiotics- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
- Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
IndicationsFirst choice
Typhoid fever Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Paratyphoid fever Other specified pneumonia (Hospital-acquired pneumonia) Bacterial meningitis co-prescribed with amikacin Acute pyelonephritis (severe) co-prescribed with amikacin Inflammatory and other diseases of prostate (severe) co-prescribed with azithromycin Gonococcal infection co-prescribed with clarithromycin Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with metronidazole Necrotising fasciitis co-prescribed with metronidazole Peritonitis (mild-moderate) co-prescribed with metronidazole Peritonitis (severe) co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritoneal abscess (severe) co-prescribed with vancomycin Endophthalmitis -
Cefuroxime General information
SectionWatch group antibiotics- Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
-
Certolizumab pegol General information
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritisSectionMedicines for juvenile joint diseasesIndicationsTherapeutic equivalent to adalimumab for Juvenile idiopathic arthritis -
Cetirizine General information
SectionAntiallergics and medicines used in anaphylaxisIndicationsTherapeutic equivalent to loratadine for Allergic or hypersensitivity conditions of unspecified type -
Chlorambucil General information
SectionCytotoxic medicines- Oral > Solid: 2 mg tablet
-
Chloramphenicol General information
SectionAccess group antibiotics- Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
- Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
-
Chlorhexidine General information
SectionMedicines administered to the neonate [c]- Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
- Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
IndicationsSectionAntiseptics- Local > Topical > Solution: 5% (digluconate) for dilution
Indications -
Chlorine base compound General information
SectionDisinfectants- Local > Topical > Powder: 0.1% available chlorine for solution
- Local > Topical > Liquid: 0.1% available chlorine for solution
- Local > Topical > Solid: 0.1% available chlorine for solution
Indications -
Chloroquine General information
SectionAntimalarial medicines > For curative treatment- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
IndicationsSectionAntimalarial medicines > For chemoprevention- Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
- Oral > Solid: 150 mg tablet (as phosphate or sulfate)
SectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
Indications -
Chlorothiazide General information
SectionAntihypertensive medicinesIndicationsTherapeutic equivalent to hydrochlorothiazide for Essential hypertensionSectionMedicines used in heart failureIndicationsTherapeutic equivalent to hydrochlorothiazide for Heart failure -
Chloroxylenol General information
SectionDisinfectants- Local > Topical > Solution: 4.8%
Indications -
Chlorpromazine General information
SectionMedicines for psychotic disorders- Oral > Liquid: 25 mg per 5 mL (hydrochloride)
- Oral > Solid: 100 mg (hydrochloride)
IndicationsTherapeutic equivalent to haloperidol for Schizophrenia or other primary psychotic disorders -
Chlortalidone General information
SectionAntihypertensive medicinesIndicationsTherapeutic equivalent to hydrochlorothiazide for Essential hypertensionSectionMedicines used in heart failureIndicationsTherapeutic equivalent to hydrochlorothiazide for Heart failure -
Chlortetracycline General information
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to tetracycline for Other specified conjunctivitis Therapeutic equivalent to tetracycline for Infectious keratitis Therapeutic equivalent to tetracycline for Infectious blepharitis Therapeutic equivalent to tetracycline for Trachoma -
Cholera vaccine General information
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Ciclesonide General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide for Asthma -
Ciclosporin General information
SectionImmunomodulators for non-malignant disease- Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
- Oral > Liquid: 100 mg per mL
- Oral > Solid > capsule: 25 mg
-
Ciprofloxacin General information
SectionEar, nose and throat medicines [c]- Local > Otological > drops: 0.3% (as hydrochloride)
IndicationsSectionWatch group antibiotics- Parenteral > General injections > IV: 2 mg per mL (as hyclate)
- Oral > Liquid: 250 mg per 5 mL (anhydrous)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)
- Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
IndicationsFirst choice
Neutropenia (low-risk) Inflammatory and other diseases of prostate (mild to moderate) Typhoid fever Paratyphoid fever Infectious gastroenteritis or colitis without specification of infectious agent Acute pyelonephritis (mild to moderate)Second choice
Cholera Cholera [children] co-prescribed with metronidazole Peritoneal abscess (mild-moderate) co-prescribed with metronidazole Peritonitis (mild-moderate) -
Cisplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
IndicationsOther specified gliomas of brain Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri -
Cladribine General information
SectionMedicines for multiple sclerosis- Oral > Solid > tablet: 10 mg
Indications -
Clarithromycin General information
SectionWatch group antibiotics- Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Oral > Solid > dosage form: 500 mg; 250 mg
- Oral > Solid > dosage form: 500 mg
IndicationsFirst choice
co-prescribed with cefotaxime Bacterial pneumonia (Community-acquired pneumonia - severe) co-prescribed with ceftriaxone Bacterial pneumonia (Community-acquired pneumonia - severe)Second choice
Acute pharyngitis co-prescribed with amoxicillin + clavulanic acid Bacterial pneumonia (Community-acquired pneumonia - severe)Other indications -
Clindamycin General information
SectionAccess group antibiotics- Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
- Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)
-
Clofazimine General information
SectionAntituberculosis medicines- Oral > Solid: 100 mg; 50 mg
IndicationsSectionAntileprosy medicines- Oral > Solid: 100 mg; 50 mg
Indications -
Clomifene General information
SectionOvulation inducers- Oral > Solid: 50 mg (citrate)
-
Clomipramine General information
SectionMedicines for obsessive compulsive disorders- Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
Indications -
Clopidogrel General information
SectionAnti-platelet medicines- Oral > Solid: 75 mg; 300 mg
-
Clotrimazole General information
SectionAntifungal medicines- Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
Indications -
Cloxacillin General information
SectionAccess group antibiotics- Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid
- Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection
- Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)
IndicationsFirst choice
Bacterial infection of joint Osteomyelitis or osteitis Bacterial cellulitis, erysipelas or lymphangitisSecond choice
co-prescribed with amikacin Sepsis without septic shock -
Clozapine General information
SectionMedicines for psychotic disorders- Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
-
Coagulation factor IX General information
SectionBlood coagulation factors- Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
-
Coagulation factor IX complex General information
SectionBlood coagulation factorsIndicationsTherapeutic equivalent to coagulation factor IX for Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX for Haemophilia B -
Coagulation factor VIII General information
SectionBlood coagulation factors- Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection
Indications -
Coal tar General information
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Solution: 5%
Indications -
Codeine General information
SectionOpioid analgesics- Oral > Solid: 30 mg tablet (codeine phosphate)
Indications -
Colecalciferol General information
SectionVitamins and minerals- Oral > Liquid: 400 IU per mL
- Oral > Solid: 400 IU; 1000 IU
IndicationsCalcium deficiency Vitamin D deficiency Therapeutic equivalent to ergocalciferol for Vitamin D deficiency Therapeutic equivalent to ergocalciferol for Calcium deficiency -
Colistin (injection) General information
SectionReserve group antibiotics- Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium) (equivalent to 34 mg colistin base activity)
-
Compound sodium lactate solution General information
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: injectable solution
-
Condoms General information
SectionBarrier methods- -
-
Copper-containing intrauterine device General information
SectionIntrauterine devices- -
-
Cryoprecipitate (not pathogen-reduced) General information
SectionBlood and blood componentsIndicationsTherapeutic equivalent to cryoprecipitate (pathogen-reduced) for Haemophilia A Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Von Willebrand disease Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Obstetric haemorrhage -
Cryoprecipitate (pathogen-reduced) General information
SectionBlood and blood components- Injection: frozen liquid in bag or lyophilized powder in vial containing:
- > 50 IU Factor VIII
- > 100 IU vWF
- > 140 mg clottable fibrinogen per unit
-
Cyclizine General information
SectionMedicines for other common symptoms in palliative care- Oral > Solid: 50 mg tablet
- Parenteral > General injections > unspecified: 50 mg per mL
Indications -
Cyclopentolate General information
SectionDiagnostic agents > Ophthalmic medicinesIndicationsTherapeutic equivalent to tropicamide for Cycloplegic drugSectionOphthalmological preparations > MydriaticsIndicationsTherapeutic equivalent to atropine for Anterior uveitis -
Cyclophosphamide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid > dosage form: 25 mg; 50 mg
IndicationsOther specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Chronic lymphocytic leukaemia or small lymphocytic lymphoma Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Other specified gliomas of brain Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive -
Cycloserine General information
SectionAntituberculosis medicines- Oral > Solid: 250 mg; 125 mg
Indications -
Cytarabine General information
SectionCytotoxic medicines- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial
Indications -
Dabigatran General information
SectionMedicines affecting coagulation- Oral > Solid: 110 mg; 150 mg
-
Dacarbazine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
Indications -
Daclatasvir General information
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid > tablet: 30 mg (as hydrochloride); 60 mg (as hydrochloride)
Indications -
Daclatasvir + sofosbuvir General information
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid > tablet: 60 mg + 400 mg
Indications -
Dactinomycin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 µg in vial powder for injection
-
Dalteparin General information
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism -
Dapagliflozin General information
SectionOral hypoglycaemic agentsIndicationsTherapeutic equivalent to empagliflozin for Type 2 diabetes mellitus -
Dapsone General information
SectionAntileprosy medicines- Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
Indications -
Darbepoetin alfa General information
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease -
Darunavir General information
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
-
Dasatinib General information
SectionTargeted therapies- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
-
Daunorubicin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
-
Deferasirox General information
SectionOther medicines for haemoglobinopathies- Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
- Oral > Solid > tablet: 90 mg; 180 mg; 360 mg
IndicationsOther specified sickle cell disorders or other haemoglobinopathies Thalassaemias Therapeutic equivalent to deferoxamine for Thalassaemias -
Deferiprone General information
SectionOther medicines for haemoglobinopathiesIndicationsTherapeutic equivalent to deferasirox for Other specified sickle cell disorders or other haemoglobinopathies Therapeutic equivalent to deferasirox for Thalassaemias -
Deferoxamine General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
SectionOther medicines for haemoglobinopathies- Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
-
Delamanid General information
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 25 mg
- Oral > Solid > tablet: 50 mg
Indications -
Dengue vaccine General information
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
-
Desmopressin General information
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
- Local > Nasal > Spray: 10 µg per dose (acetate)
Indications -
Dexamethasone General information
SectionOther medicines administered to the mother- Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
SectionHormones and antihormones- Oral > Solid: 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
SectionAntiallergics and medicines used in anaphylaxis- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
IndicationsSectionAntiemetic medicines- Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
- Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
Indications -
Dextran 70 General information
SectionPlasma substitutes- Parenteral > General injections > IV: 6% injectable solution
Indications -
Diaphragms General information
SectionBarrier methods- -
-
Diazepam General information
SectionAntiseizure medicines- Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
- Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 5 mg; 10 mg
- Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system
- Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube
- Parenteral > General injections > unspecified: 5 mg per mL
IndicationsSectionMedicines for anxiety disorders- Oral > Solid: 5 mg (scored); 2 mg (scored)
Indications -
Diazoxide General information
SectionMedicines for hypoglycaemia- Oral > Liquid: 50 mg per mL
- Oral > Solid: 50 mg
-
Diethylcarbamazine General information
SectionAntifilarials- Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
Indications -
Digoxin General information
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
- Oral > Liquid: 50 µg per mL
- Oral > Solid: 62.5 µg; 250 µg
IndicationsSectionMedicines used in heart failure- Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule
- Oral > Liquid: 50 µg per mL
- Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg
Indications -
Dihydroartemisinin + piperaquine phosphate General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet
-
Diloxanide General information
SectionAntiamoebic and antigiardiasis medicines- Oral > Solid: 500 mg (furoate)
Indications -
Dimercaprol General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule
-
Diphtheria antitoxin General information
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
Indications -
Diphtheria vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Docetaxel General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL
-
Docusate sodium General information
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 50 mg per 5 mL oral liquid
- Oral > Solid: 100 mg capsule
Indications -
Dolasetron General information
SectionMedicines for other common symptoms in palliative careIndicationsTherapeutic equivalent to ondansetron for Palliative careSectionAntiemetic medicinesIndicationsTherapeutic equivalent to ondansetron for Nausea or vomiting -
Dolutegravir General information
SectionAntiretrovirals > Integrase inhibitors- Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)
-
Dolutegravir + lamivudine + tenofovir General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Dopamine General information
SectionMedicines used in heart failure- Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
Indications -
Doxorubicin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
IndicationsMalignant neoplasms of breast Hodgkin lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Other specified malignant neoplasms of breast Anaplastic large cell lymphoma, ALK-positive Ewing sarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site -
Doxorubicin (as pegylated liposomal) General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
Indications -
Doxycycline General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)
IndicationsSectionAntimalarial medicines > For chemoprevention- Oral > Solid: 100 mg (hydrochloride or hyclate)
IndicationsSectionAccess group antibiotics- Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Oral > Solid > dispersible tablet: 100 mg (as monohydrate)
- Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
- Oral > Solid > dosage form: 100 mg (as hyclate)
-
Edoxaban General information
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation -
Efavirenz General information
SectionAntiretrovirals > Non-nucleoside reverse transcriptase inhibitors- Oral > Solid: 600 mg tablet
-
Efavirenz + emtricitabine + tenofovir General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Efavirenz + lamivudine + tenofovir General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
Indications -
Eflornithine General information
SectionMedicines for the treatment of 2nd stage African trypanosomiasis- Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)
Indications -
Empagliflozin General information
SectionOral hypoglycaemic agents- Oral > Solid: 10 mg; 25 mg
Indications -
Emtricitabine + tenofovir General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
-
Enalapril General information
SectionAntihypertensive medicines- Oral > Liquid: 1 mg per mL (as hydrogen maleate)
- Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
IndicationsSectionMedicines used in heart failure- Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
Indications -
Enoxaparin General information
SectionMedicines affecting coagulation- Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule
Indications -
Entecavir General information
SectionMedicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Liquid: 0.05 mg per mL
- Oral > Solid: 0.5 mg; 1 mg
Indications -
Enzalutamide General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to abiraterone for Malignant neoplasms of prostate -
Ephedrine General information
SectionLocal anaesthetics- Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
-
Epinephrine General information
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
IndicationsSectionOphthalmological preparations > Mydriatics- Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
IndicationsSectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
IndicationsSectionAntiallergics and medicines used in anaphylaxis- Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
Indications -
Epoetin alfa General information
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease -
Epoetin beta General information
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease -
Epoetin theta General information
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease -
Equine rabies immunoglobulin General information
SectionImmunologicals > Sera, immunoglobulins and monoclonal antibodies- Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
Indications -
Ergocalciferol General information
SectionVitamins and minerals- Oral > Liquid: 250 µg per mL (10 000 IU per mL)
- Oral > Solid: 1.25 mg (50 000 IU)
IndicationsTherapeutic equivalent to colecalciferol for Calcium deficiency Therapeutic equivalent to colecalciferol for Vitamin D deficiency Vitamin D deficiency Calcium deficiency -
Ergometrine General information
SectionUterotonics- Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
Indications -
Erlotinib General information
SectionTargeted therapies- Oral > Solid: 100 mg; 150 mg
-
Erythromycin General information
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Ointment: 0.5%
IndicationsSectionWatch group antibiotics -
Erythropoiesis-stimulating agents General information
SectionAntianaemia medicines- Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
Indications -
Estradiol cypionate + medroxyprogesterone acetate General information
SectionInjectable hormonal contraceptives- Parenteral > General injections > IM: 5 mg + 25 mg
-
Etanercept General information
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritisSectionMedicines for juvenile joint diseasesIndicationsTherapeutic equivalent to adalimumab for Juvenile idiopathic arthritis -
Ethambutol General information
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)
Indications -
Ethambutol + isoniazid + pyrazinamide + rifampicin General information
SectionAntituberculosis medicines- Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
Indications -
Ethambutol + isoniazid + rifampicin General information
SectionAntituberculosis medicines- Oral > Solid: 275 mg + 75 mg + 150 mg tablet
Indications -
Ethanol General information
SectionAntiseptics- Local > Topical > Solution: 70% (denatured)
Indications -
Ethinylestradiol + etonogestrel General information
SectionIntravaginal contraceptives- Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg
-
Ethinylestradiol + levonorgestrel General information
SectionOral hormonal contraceptives- Oral > Solid: 30 µg + 150 µg
-
Ethinylestradiol + norethisterone General information
SectionOral hormonal contraceptives- Oral > Solid: 35 µg + 1 mg
-
Ethionamide General information
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 125 mg
- Oral > Solid > tablet: 250 mg
-
Ethosuximide General information
SectionAntiseizure medicines- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid: 250 mg
Indications -
Etonogestrel-releasing implant General information
SectionImplantable contraceptives- Implant > Subdermal: 68 mg single rod
-
Etoposide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
- Oral > Solid: 100 mg capsule; 50 mg capsule
IndicationsBurkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative -
Everolimus General information
SectionTargeted therapies- Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
- Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
Indications -
Fentanyl General information
SectionOpioid analgesics- Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
Indications -
Ferrous salt General information
SectionAntianaemia medicines- Oral > Liquid: 25 mg per mL iron (as sulfate)
- Oral > Solid: 60 mg iron
Indications -
Ferrous salt + folic acid General information
SectionAntianaemia medicines- Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg
-
Fexinidazole General information
SectionMedicines for the treatment of 1st stage African trypanosomiasis- Oral > Solid: 600 mg
IndicationsSectionMedicines for the treatment of 2nd stage African trypanosomiasis- Oral > Solid: 600 mg
Indications -
Fexofenadine General information
SectionAntiallergics and medicines used in anaphylaxisIndicationsTherapeutic equivalent to loratadine for Allergic or hypersensitivity conditions of unspecified type -
Filgrastim General information
SectionImmunomodulators- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
Indications -
Fluconazole General information
SectionAntifungal medicines- Parenteral > General injections > IV: 2 mg per mL in vial
- Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid
- Oral > Solid > capsule: 50 mg
Indications -
Flucytosine General information
SectionAntifungal medicines- Parenteral > General injections > IV: 2.5 g per 250 mL infusion
- Oral > Solid: 250 mg capsule
Indications -
Fludarabine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)
-
Fludrocortisone General information
SectionAdrenal hormones and synthetic substitutes- Oral > Solid: 100 µg (acetate)
Indications -
Flunisolide General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide for Asthma -
Fluorescein General information
SectionDiagnostic agents > Ophthalmic medicines- Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
Indications -
Fluoride General information
SectionDental medicines and preparations- Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)
- Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)
- Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)
- Local > Dental > Varnish: 22500 ppm fluoride (any type)
Indications -
Fluorouracil General information
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Ointment: 5%
IndicationsSectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg per mL in vial
-
Fluoxetine General information
SectionMedicines for depressive disorders- Oral > Solid: 20 mg (as hydrochloride)
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Solid: 20 mg (as hydrochloride)
IndicationsSectionMedicines for anxiety disorders- Oral > Solid: 20 mg (as hydrochloride)
SectionMedicines for obsessive compulsive disorders- Oral > Solid: 20 mg (as hydrochloride)
Indications -
Fluphenazine General information
SectionMedicines for psychotic disorders- Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
-
Flutamide General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to bicalutamide for Malignant neoplasms of prostate -
Fluticasone General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide for Asthma -
Fluticasone + formoterol General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol for Asthma -
Fluticasone furoate + vilanterol General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol for Asthma -
Fluvastatin General information
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis -
Folic acid General information
SectionAntianaemia medicines- Oral > Solid: 1 mg tablet; 5 mg tablet
- Oral > Solid: 400 µg
-
Fomepizole General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)
-
Fosfomycin (injection) General information
SectionReserve group antibiotics- Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
-
Fresh-frozen plasma General information
SectionBlood and blood components- Parenteral > General injections > IV:
Indications -
Furosemide General information
SectionMedicines used in heart failure- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
- Oral > Solid > tablet: 40 mg; 20 mg
IndicationsSectionDiuretics- Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL
- Oral > Solid > tablet: 40 mg; 20 mg
Indications -
Gefitinib General information
SectionTargeted therapiesIndicationsTherapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung -
Gemcitabine General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
-
Gentamicin General information
SectionAccess group antibiotics- Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)
IndicationsFirst choice
Neonatal meningitis co-prescribed with amoxicillin Sepsis without septic shock co-prescribed with amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Sepsis without septic shock co-prescribed with ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with ampicillin Peritoneal abscess (severe) co-prescribed with ampicillin Peritonitis (mild-moderate) co-prescribed with ampicillin Peritonitis (severe) co-prescribed with ampicillin Peritoneal abscess (mild-moderate) co-prescribed with benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with benzylpenicillin Sepsis without septic shockSectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)
Indications -
Glass ionomer cement General information
SectionDental medicines and preparations- Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid
Indications -
Glatiramer acetate General information
SectionMedicines for multiple sclerosis- Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe
Indications -
Glecaprevir + pibrentasvir General information
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid: 50 mg + 20 mg granules
- Oral > Solid > tablet: 100 mg + 40 mg
Indications -
Gliclazide General information
SectionOral hypoglycaemic agents- Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
Indications -
Glucagon General information
SectionMedicines for hypoglycaemia- Parenteral > General injections > unspecified: 1 mg per mL
Indications -
Glucose General information
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
- Parenteral > General injections > IV: 50% hypertonic
-
Glucose + sodium chloride General information
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
-
Glutaral General information
SectionDisinfectants- Local > Topical > Solution: 2%
Indications -
Glyceryl trinitrate General information
SectionAntianginal medicines- Oral > Solid: 500 µg sublingual tablet
Indications -
Glycopyrronium General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to tiotropium bromide for Chronic obstructive pulmonary disease -
Golimumab General information
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritisSectionMedicines for juvenile joint diseasesIndicationsTherapeutic equivalent to adalimumab for Juvenile idiopathic arthritis -
Goserelin General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate -
Granisetron General information
SectionMedicines for other common symptoms in palliative careIndicationsTherapeutic equivalent to ondansetron for Palliative careSectionAntiemetic medicinesIndicationsTherapeutic equivalent to ondansetron for Nausea or vomiting -
Griseofulvin General information
SectionAntifungal medicines- Oral > Liquid: 125 mg per 5 mL
- Oral > Solid: 125 mg; 250 mg
Indications -
Haemophilus influenzae type b vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Haloperidol General information
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per mL
- Oral > Solid: 0.5 mg; 2 mg; 5 mg
- Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
IndicationsSectionMedicines for psychotic disorders- Parenteral > General injections > IM: 5 mg per mL in ampoule
- Oral > Solid: 2 mg; 5 mg
-
Haloperidol decanoate General information
SectionMedicines for psychotic disordersIndicationsTherapeutic equivalent to fluphenazine for Schizophrenia or other primary psychotic disorders -
Halothane General information
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation > liquid:
Indications -
Heparin sodium General information
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule; 20000 IU per mL in 1 mL ampoule; 5000 IU per mL in 1 mL ampoule
-
Hepatitis A vaccine General information
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Hepatitis B vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Homatropine General information
SectionOphthalmological preparations > MydriaticsIndicationsTherapeutic equivalent to atropine for Anterior uveitis -
Human papilloma virus (HPV) vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Hydralazine General information
SectionAntihypertensive medicines- Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
- Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
Indications -
Hydrochlorothiazide General information
SectionAntihypertensive medicines- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 25 mg; 12.5 mg
IndicationsSectionMedicines used in heart failure- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 25 mg
IndicationsSectionDiuretics- Oral > Solid: 25 mg
Indications -
Hydrocortisone General information
SectionHormones and antihormones- Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
SectionAdrenal hormones and synthetic substitutes- Oral > Solid: 5 mg; 10 mg; 20 mg
IndicationsSectionAntiallergics and medicines used in anaphylaxis- Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
IndicationsSectionAnti-inflammatory medicines- Local > Rectal > Suppository: 25 mg (acetate)
- Local > Rectal > Retention enema: 100 mg per 60 mL
IndicationsSectionDermatological medicines > Anti-inflammatory and antipruritic medicines- Local > Topical > Cream: 1% (acetate)
- Local > Topical > Ointment: 1% (acetate)
-
Hydromorphone General information
-
Hydroxocobalamin General information
SectionAntianaemia medicines- Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
-
Hydroxycarbamide (hydroxyurea) General information
SectionCytotoxic medicines- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
SectionOther medicines for haemoglobinopathies- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg
-
Hydroxychloroquine General information
SectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid: 200 mg (as sulfate)
-
Hyoscine butylbromide General information
SectionMedicines for other common symptoms in palliative care- Parenteral > General injections > unspecified: 20 mg per mL injection
Indications -
Hyoscine hydrobromide General information
SectionMedicines for other common symptoms in palliative care- Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
- Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
Indications -
Ibrutinib General information
SectionTargeted therapies- Oral > Solid: 140 mg
-
Ibuprofen General information
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 5 mg per mL
IndicationsSectionNon-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)- Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL
- Oral > Solid > tablet: 200 mg; 400 mg; 600 mg
IndicationsSectionAntimigraine medicines > For treatment of acute attack- Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL
- Oral > Solid > tablet: 200 mg; 400 mg
Indications -
Ifosfamide General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
IndicationsOther specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive -
Imatinib General information
SectionTargeted therapies- Oral > Solid: 100 mg; 400 mg
-
Imipenem + cilastatin General information
SectionAntituberculosis medicinesIndicationsTherapeutic equivalent to meropenem for Multi-drug resistant Mycobacterium tuberculosisSectionWatch group antibioticsIndicationsSecond choice
Therapeutic equivalent to meropenem for Neutropenia (high-risk) Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Peritonitis (severe) -
Indapamide General information
SectionAntihypertensive medicinesIndicationsTherapeutic equivalent to hydrochlorothiazide for Essential hypertensionSectionMedicines used in heart failureIndicationsTherapeutic equivalent to hydrochlorothiazide for Heart failure -
Indometacin General information
SectionMedicines administered to the neonate [c]IndicationsTherapeutic equivalent to ibuprofen for Patent arterial duct -
Infliximab General information
SectionImmunomodulators for non-malignant diseaseIndicationsTherapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritisSectionMedicines for juvenile joint diseasesIndicationsTherapeutic equivalent to adalimumab for Juvenile idiopathic arthritis -
Influenza vaccine (seasonal) General information
SectionRecommendations for immunization programmes with certain characteristics- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Insulin General information
SectionInsulins- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen (soluble)
Indications -
Insulin degludec General information
SectionInsulinsIndicationsTherapeutic equivalent to long-acting insulin analogues for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 2 diabetes mellitus -
Insulin detemir General information
SectionInsulinsIndicationsTherapeutic equivalent to long-acting insulin analogues for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 2 diabetes mellitus -
Insulin glargine General information
SectionInsulinsIndicationsTherapeutic equivalent to long-acting insulin analogues for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 2 diabetes mellitus -
Intermediate-acting insulin General information
SectionInsulins- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
Indications -
Intraperitoneal dialysis solution General information
SectionPeritoneal dialysis solution- parenteral solution
Indications -
Iodine General information
SectionVitamins and minerals- Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
- Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
- Oral > Solid: 190 mg
IndicationsSectionAntisepticsIndicationsTherapeutic equivalent to povidone iodine for Povidone iodine -
Iohexol General information
SectionDiagnostic agents > Radiocontrast media- Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
Indications -
Ipratropium bromide General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Respiratory > Inhalation > aerosol: 20 µg per dose
Indications -
Irinotecan General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
-
Isoflurane General information
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation > liquid:
Indications -
Isoniazid General information
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 100 mg; 300 mg
Indications -
Isoniazid + pyrazinamide + rifampicin General information
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg
Indications -
Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim General information
SectionMedicines for prevention of HIV-related opportunistic infections- Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
Indications -
Isoniazid + rifampicin General information
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 50 mg + 75 mg
- Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg
Indications -
Isoniazid + rifapentine General information
SectionAntituberculosis medicines- Oral > Solid: 300 mg + 300 mg tablet (scored)
Indications -
Isosorbide dinitrate General information
SectionAntianginal medicines- Oral > Solid: 5 mg sublingual tablet
Indications -
Itraconazole General information
SectionAntifungal medicines- Oral > Liquid: 10 mg per mL
- Oral > Solid: 100 mg
-
Ivermectin General information
SectionIntestinal anthelminthics- Oral > Solid > tablet: 3 mg
SectionAntifilarials- Oral > Solid > tablet: 3 mg
IndicationsSectionMedicines for ectoparasitic infections- Oral > Solid > tablet: 3 mg
Indications -
Kanamycin General information
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis -
Ketamine General information
SectionGeneral anaesthetics and oxygen > Injectable medicines- Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)
Indications -
Lactulose General information
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid
Indications -
Lamivudine General information
SectionAntiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 150 mg tablet
-
Lamivudine + tenofovir General information
SectionFixed-dose combinations of antiretroviralsIndicationsTherapeutic equivalent to emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to emtricitabine + tenofovir for Contact with or exposure to human immunodeficiency virus -
Lamivudine + zidovudine General information
SectionFixed-dose combinations of antiretrovirals- Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
-
Lamotrigine General information
SectionAntiseizure medicines- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
Indications -
Latanoprost General information
SectionOphthalmological preparations > Miotics and antiglaucoma medicines- Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
Indications -
Ledipasvir + sofosbuvir General information
SectionMedicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations- Oral > Solid: 90 mg + 400 mg tablet
Indications -
Lenalidomide General information
SectionImmunomodulators- Oral > Solid: 25 mg
Indications -
Letrozole General information
SectionOvulation inducers- Oral > Solid > dosage form: 2.5 mg
-
Leuprorelin General information
SectionHormones and antihormones- Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
-
Levamisole General information
SectionIntestinal anthelminthics- Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)
Indications -
Levetiracetam General information
SectionAntiseizure medicines- Oral > Liquid: 100 mg per mL
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg
- Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag
Indications -
Levodopa + benserazide General information
SectionMedicines for parkinsonismIndicationsTherapeutic equivalent to levodopa + carbidopa for Parkinson disease -
Levodopa + carbidopa General information
SectionMedicines for parkinsonism- Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
Indications -
Levofloxacin General information
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 250 mg; 500 mg; 750 mg
Indications -
Levonorgestrel General information
SectionOral hormonal contraceptives- Oral > Solid: 750 µg [2]; 1.5 mg [1]
- Oral > Solid: 30 µg
SectionIntrauterine devices- Intrauterine system with reservoir containing 52 mg of levonorgestrel.
-
Levonorgestrel-releasing implant General information
SectionImplantable contraceptives- Implant > Subdermal: 75 mg per rod (two-rods)
-
Levothyroxine General information
SectionThyroid hormones and antithyroid medicines- Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
Indications -
Lidocaine General information
SectionAntiarrhythmic medicines- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
IndicationsSectionLocal anaesthetics- Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
- Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
- Local > Topical > unspecified: 2 to 4% (hydrochloride)
Indications -
Lidocaine + epinephrine General information
SectionLocal anaesthetics- Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
- Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
Indications -
Linezolid General information
SectionReserve group antibiotics- Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
- Oral > Liquid: 100 mg per 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 600 mg
Indications -
Lisinopril + amlodipine General information
SectionAntihypertensive medicines- Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
Indications -
Lisinopril + hydrochlorothiazide General information
SectionAntihypertensive medicines- Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
Indications -
Lithium carbonate General information
SectionMedicines for bipolar disorders- Oral > Solid: 300 mg
Indications -
Long-acting insulin analogues General information
SectionInsulins- Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
Indications -
Loperamide General information
SectionMedicines for other common symptoms in palliative care- Oral > Solid > dosage form: 2 mg
Indications -
Lopinavir + ritonavir General information
SectionAntiretrovirals > Protease inhibitors- Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)
- Oral > Solid > dosage form: 40 mg + 10 mg
-
Loratadine General information
SectionAntiallergics and medicines used in anaphylaxis- Oral > Liquid: 1 mg per mL
- Oral > Solid: 10 mg
-
Lorazepam General information
SectionAntiseizure medicines- Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
Indications -
Losartan General information
SectionAntihypertensive medicines- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
IndicationsSectionMedicines used in heart failure- Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
Indications -
Lovastatin General information
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis -
Lugol's solution General information
SectionThyroid hormones and antithyroid medicines- Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)
Indications -
Magnesium sulfate General information
SectionAntiseizure medicines- Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
- Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
Indications -
Mannitol General information
SectionDiuretics- Parenteral > General injections > IV: 10% solution; 20% solution
Indications -
Measles vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Mebendazole General information
SectionIntestinal anthelminthics- Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
IndicationsSectionCysticidal medicines- Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)
Indications -
Medroxyprogesterone acetate General information
SectionInjectable hormonal contraceptives- Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
- Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
SectionProgestogens- Oral > Solid: 5 mg
Indications -
Mefloquine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 250 mg tablet (hydrochloride)
SectionAntimalarial medicines > For chemoprevention- Oral > Solid: 250 mg tablet (hydrochloride)
Indications -
Meglumine antimoniate General information
SectionAntileishmaniasis medicines- Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule
-
Meglumine iotroxate General information
SectionDiagnostic agents > Radiocontrast media- Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
Indications -
Melarsoprol General information
SectionMedicines for the treatment of 2nd stage African trypanosomiasis- Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
Indications -
Melphalan General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg
Indications -
Meningococcal meningitis vaccine General information
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
-
Mercaptopurine General information
SectionCytotoxic medicines- Oral > Liquid: 20 mg per mL
- Oral > Solid: 50 mg tablet
-
Meropenem General information
SectionWatch group antibiotics- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
IndicationsSectionAntituberculosis medicines- Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
Indications -
Meropenem + vaborbactam General information
SectionReserve group antibiotics- Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
-
Mesalazine General information
SectionAnti-inflammatory medicinesIndicationsTherapeutic equivalent to sulfasalazine for Crohn disease site Therapeutic equivalent to sulfasalazine for Ulcerative colitis -
Mesna General information
SectionSupportive medicines- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg
IndicationsOsteosarcoma of bone and articular cartilage of other specified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis -
Metformin General information
SectionOral hypoglycaemic agents- Oral > Solid: 500 mg (hydrochloride)
Indications -
Methadone General information
SectionMedicines for opioid use disorders- Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
IndicationsSectionOpioid analgesics- Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
- Oral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)
Indications -
Methimazole General information
SectionThyroid hormones and antithyroid medicines- Oral > Solid: 5 mg; 10 mg; 20 mg
Indications -
Methotrexate General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
- Oral > Solid: 2.5 mg (as sodium salt)
IndicationsLymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosisSectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)
IndicationsSectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid > tablet: 2.5 mg (as sodium salt)
IndicationsSectionMedicines for juvenile joint diseases- Oral > Solid > tablet: 2.5 mg (as sodium salt)
Indications -
Methoxy polyethylene glycol-epoetin beta General information
SectionAntianaemia medicinesIndicationsTherapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease -
Methyldopa General information
SectionAntihypertensive medicines- Oral > Solid: 250 mg
Indications -
Methylergometrine General information
SectionUterotonicsIndicationsTherapeutic equivalent to ergometrine for Postpartum haemorrhage -
Methylprednisolone General information
SectionHormones and antihormones- Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
-
Methylthioninium chloride General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
Indications -
Metoclopramide General information
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 5 mg per 5 mL
- Oral > Solid: 10 mg (hydrochloride)
- Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
IndicationsSectionAntiemetic medicines- Oral > Liquid: 5 mg per 5 mL
- Oral > Solid: 10 mg (hydrochloride)
- Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
Indications -
Metoprolol General information
SectionAntianginal medicinesIndicationsTherapeutic equivalent to bisoprolol for Angina pectorisSectionMedicines used in heart failureIndicationsTherapeutic equivalent to bisoprolol for Heart failureSectionAntihypertensive medicinesIndicationsTherapeutic equivalent to bisoprolol for Essential hypertensionSectionAntiarrhythmic medicinesIndicationsTherapeutic equivalent to bisoprolol for Cardiac arrhythmia -
Metronidazole General information
SectionAntiamoebic and antigiardiasis medicines- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Parenteral > General injections > unspecified: 500 mg in 100 mL vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
IndicationsSectionAccess group antibiotics- Oral > Liquid: 200 mg per 5 mL (as benzoate)
- Local > Rectal > Suppository: 500 mg; 1 g
- Parenteral > General injections > unspecified: 500 mg per 100 mL in vial
- Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg
IndicationsFirst choice
Intestinal infections due to Clostridioides difficile Trichomoniasis co-prescribed with cefazolin Other specified prophylactic measures co-prescribed with cefotaxime Peritonitis (severe) co-prescribed with cefotaxime Peritonitis (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (severe) co-prescribed with ceftriaxone Necrotising fasciitis co-prescribed with ceftriaxone Peritonitis (severe) co-prescribed with ceftriaxone Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritoneal abscess (severe) co-prescribed with ceftriaxone Peritonitis (mild-moderate)Second choice
co-prescribed with ciprofloxacin Peritonitis (mild-moderate) co-prescribed with ciprofloxacin Peritoneal abscess (mild-moderate) -
Micafungin General information
SectionAntifungal medicines- Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection
Indications -
Miconazole General information
SectionDermatological medicines > Antifungal medicines- Local > Topical > Cream: 2% (nitrate)
- Local > Topical > Ointment: 2% (nitrate)
Indications -
Midazolam General information
SectionAntiseizure medicines- Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)
- Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)
IndicationsSectionPreoperative medication and sedation for short-term procedures- Parenteral > General injections > IV: 1 mg per mL
- Oral > Liquid: 2 mg per mL
- Oral > Solid > dosage form: 15 mg; 7.5 mg
IndicationsSectionMedicines for other common symptoms in palliative care- Oral > Liquid: 2 mg per mL
- Parenteral > General injections > unspecified: 1 mg per mL; 5 mg per mL
- Oral > Solid > dosage form: 7.5 mg; 15 mg
Indications -
Mifepristone - misoprostol General information
SectionUterotonics- Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
-
Miltefosine General information
SectionAntileishmaniasis medicines- Oral > Solid: 10 mg; 50 mg
-
Misoprostol General information
SectionUterotonics- Oral > Solid: 200 µg
- Local > Vaginal > tablet: 25 µg
-
Mometasone General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide for Asthma -
Mometasone + formoterol General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary diseaseIndicationsTherapeutic equivalent to budesonide + formoterol for Asthma -
Morphine General information
SectionOpioid analgesics- Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
- Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
- Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
- Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
IndicationsSectionPreoperative medication and sedation for short-term procedures- Parenteral > General injections > IV: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
-
Moxifloxacin General information
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 100 mg
- Oral > Solid > tablet: 400 mg
-
Multiple micronutrient powder General information
SectionVitamins and minerals- Sachets containing:
- - iron (elemental) 12.5 mg (as coated ferrous fumarate)
- - zinc (elemental) 5 mg
- - vitamin A 300 micrograms
- - with or without other micronutrients at recommended daily values
Indications -
Multiple micronutrient supplement General information
SectionOther medicines administered to the mother- Tablet containing:
- Vit A: 800 mcg retinol activity equivalent
- Vit C: 70 mg
- Vit D: 5 mcg (200 IU)
- Vit E: 10 mg alpha tocopherol equivalent
- Vit B1: 1.4 mg
- Vit B2: 1.4 mg
- Vit B3: 18 mg niacin equivalent
- Vit B6: 1.9 mg
- Folic acid: 400 mcg
- Vit B12: 2.6 mcg
- Iron: 30 mg
- Iodine: 150 mcg
- Zinc: 15 mg
- Selenium: 65 mcg
- Copper: 2 mg
-
Mumps vaccine General information
SectionRecommendations for immunization programmes with certain characteristics- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Mupirocin General information
SectionDermatological medicines > Anti-infective medicines- Local > Topical > Cream: 2% (as mupirocin calcium)
- Local > Topical > Ointment: 2%
Indications -
Nadroparin General information
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism -
Naloxone General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
-
Naltrexone General information
SectionMedicines for alcohol use disorders- Parenteral > General injections > IM: 380 mg in vial (extended-release)
- Oral > Solid > tablet: 50 mg
Indications -
Natamycin General information
SectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Suspension: 5% eye drops
Indications -
Neostigmine General information
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Oral > Solid: 15 mg (neostigmine bromide)
- Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
Indications -
Netilmicin General information
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis -
Nevirapine General information
SectionAntiretrovirals > Non-nucleoside reverse transcriptase inhibitors- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > dispersible tablet: 50 mg
- Oral > Solid > tablet: 200 mg
-
Niclosamide General information
SectionIntestinal anthelminthics- Oral > Solid: 500 mg tablet (chewable)
-
Nicotinamide General information
SectionVitamins and minerals- Oral > Solid: 50 mg
Indications -
Nicotine replacement therapy General information
SectionMedicines for nicotine use disorders- Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
- Oral > Solid > lozenge: 2 mg; 4 mg lozenge
- Local > Buccal > Oral spray: 1 mg per actuation
- Local > Buccal > Chewing gum: 2 mg; 4 mg
Indications -
Nifedipine General information
SectionAntioxytocics (tocolytics)- Oral > Solid: 10 mg (immediate-release)
Indications -
Nifurtimox General information
SectionAmerican trypanosomiasis- Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
IndicationsSectionMedicines for the treatment of 2nd stage African trypanosomiasis- Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)
Indications -
Nilotinib General information
SectionTargeted therapies- Oral > Solid > capsule: 150 mg; 200 mg
-
Nilutamide General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to bicalutamide for Malignant neoplasms of prostate -
Nitrofurantoin General information
SectionAccess group antibiotics- Oral > Liquid: 25 mg per 5 mL oral liquid
- Oral > Solid > dosage form: 100 mg; 50 mg
-
Nitrous oxide General information
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation:
Indications -
Nivolumab General information
SectionImmunomodulators- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
Indications -
Norethisterone General information
SectionProgestogensIndicationsTherapeutic equivalent to medroxyprogesterone acetate for Excessive menstruation with irregular cycle -
Norethisterone enantate General information
SectionInjectable hormonal contraceptives- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
-
Normal immunoglobulin General information
SectionHuman immunoglobulins- Parenteral > General injections > IV: 5% protein solution; 10% protein solution
- Parenteral > General injections > IM: 16% protein solution
- Parenteral > General injections > SC: 15% protein solution; 16% protein solution
-
Nystatin General information
SectionAntifungal medicines- Oral > Liquid: 100000 IU per mL
- Local > Topical > Other: 100000 IU pessary
- Oral > Solid > dosage form: 500000 IU
- Oral > Solid > lozenge: 100000 IU
Indications -
Octreotide General information
SectionMedicines for disorders of the pituitary hormone system- Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
- Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)
Indications -
Ofloxacin General information
SectionEar, nose and throat medicines [c]IndicationsTherapeutic equivalent to ciprofloxacin for Infectious diseases of external earSectionOphthalmological preparations > Anti-infective agents- Local > Ophthalmological > Solution (eye drops): 0.3%
Indications -
Olanzapine General information
SectionMedicines for psychotic disorders- Parenteral > General injections > IM: 10 mg in vial powder for injection
IndicationsTherapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders -
Omeprazole General information
SectionAntiulcer medicines- Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
- Oral > Solid: 10 mg; 20 mg; 40 mg
- Parenteral > General injections > IV: 40 mg in vial
-
Ondansetron General information
SectionMedicines for other common symptoms in palliative care- Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
- Oral > Liquid: 4 mg per 5 mL (ondansetron base)
- Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)
IndicationsSectionAntiemetic medicines- Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
- Oral > Liquid: 4 mg per 5 mL (ondansetron base)
- Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)
Indications -
Oral rehydration salts General information
SectionOral rehydration- Powder for dilution in 200 mL, 500 mL, 1 L:
- - glucose 75 mEq
- - sodium 75 mEq or mmol/L
- - chloride 65 mEq or mmol/L
- - potassium 20 mEq or mmol/L
- - citrate 10 mmol/L
- - osmolarity 245 mOsm/L
- - glucose 13.5 g/L
- - sodium chloride 2.6 g/L
- - potassium chloride 1.5 g/L
- - trisodium citrate dihydrate 2.9 g/L
IndicationsSectionSolutions correcting water, electrolyte and acid-base disturbances > Oral- Powder for dilution in 200 mL, 500 mL, 1 L:
- - glucose 75 mEq
- - sodium 75 mEq or mmol/L
- - chloride 65 mEq or mmol/L
- - potassium 20 mEq or mmol/L
- - citrate 10 mmol/L
- - osmolarity 245 mOsm/L
- - glucose 13.5 g/L
- - sodium chloride 2.6 g/L
- - potassium chloride 1.5 g/L
- - trisodium citrate dihydrate 2.9 g/L
-
Oral rehydration salts - zinc sulfate General information
SectionMedicines used in diarrhoea- Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)
Indications -
Oseltamivir General information
SectionOther antivirals- Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
-
Oxaliplatin General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
-
Oxamniquine General information
SectionAntischistosomals and other antitrematode medicines- Oral > Liquid: 250 mg per 5 mL
- Oral > Solid > capsule: 250 mg
Indications -
Oxycodone General information
-
Oxygen General information
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation: (medical gas)
IndicationsSectionMedical gases- Respiratory > Inhalation:
Indications -
Oxytetracycline General information
SectionOphthalmological preparations > Anti-infective agentsIndicationsTherapeutic equivalent to tetracycline for Other specified conjunctivitis Therapeutic equivalent to tetracycline for Infectious keratitis Therapeutic equivalent to tetracycline for Infectious blepharitis Therapeutic equivalent to tetracycline for Trachoma -
Oxytocin General information
SectionUterotonics- Parenteral > General injections > unspecified: 10 IU per mL
Indications -
P-aminosalicylate sodium General information
SectionAntituberculosis medicines- Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution
Indications -
Paclitaxel General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 6 mg per mL
IndicationsOther specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri -
Paliperidone General information
SectionMedicines for psychotic disorders- Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)
IndicationsTherapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disorders Schizophrenia or other primary psychotic disorders -
Palonosetron General information
SectionMedicines for other common symptoms in palliative careIndicationsTherapeutic equivalent to ondansetron for Palliative careSectionAntiemetic medicinesIndicationsTherapeutic equivalent to ondansetron for Nausea or vomiting -
Pancreatic enzymes General information
SectionPancreatic enzymes- Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.
Indications -
Paracetamol (acetaminophen) General information
SectionNon-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)- Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
- Local > Rectal > Suppository: 100 mg; 250 mg
- Oral > Solid > dispersible tablet: 100 mg; 250 mg
- Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
IndicationsSectionAntimigraine medicines > For treatment of acute attack- Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL
- Local > Rectal > Suppository: 250 mg
- Oral > Solid > dispersible tablet: 100 mg; 250 mg
- Oral > Solid > tablet: 250 mg; 325 mg; 500 mg
Indications -
Paromomycin General information
SectionAntileishmaniasis medicines- Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
Indications -
Pegaspargase General information
SectionCytotoxic medicines- Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
Indications -
Pegfilgrastim General information
SectionImmunomodulators- Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
Indications -
Pembrolizumab General information
SectionImmunomodulatorsIndicationsTherapeutic equivalent to nivolumab for Melanoma of skin -
Penicillamine General information
SectionAntidotes and other substances used in poisonings > Specific- Oral > Solid: 250 mg
SectionDisease-modifying anti-rheumatic drugs (DMARDs)- Oral > Solid: 250 mg
Indications -
Pentamidine General information
SectionMedicines for the treatment of 1st stage African trypanosomiasis- Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection
IndicationsSectionAntipneumocystosis and antitoxoplasmosis medicines- Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)
Indications -
Permethrin General information
SectionDermatological medicines > Scabicides and pediculicides- Local > Topical > Lotion: 1%
- Local > Topical > Cream: 5%
Indications -
Pertussis vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Phenobarbital General information
SectionAntiseizure medicines- Oral > Liquid: 15 mg per 5 mL
- Oral > Solid: 15 to 100 mg
- Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)
Indications -
Phenoxymethylpenicillin General information
SectionAccess group antibiotics- Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
- Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
-
Phenytoin General information
SectionAntiseizure medicines- Oral > Liquid: 30 mg per 5 mL (phenytoin)
- Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)
- Oral > Solid > tablet: 50 mg (phenytoin) (chewable)
- Oral > Solid > dosage form: 25 mg (phenytoin sodium); 50 mg (phenytoin sodium); 100 mg (phenytoin sodium)
Indications -
Phytomenadione General information
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule
- Oral > Solid: 10 mg tablet
-
Pilocarpine General information
SectionOphthalmological preparations > Miotics and antiglaucoma medicines- Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
-
Piperacillin + tazobactam General information
SectionWatch group antibiotics- Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
Indications -
Platelets General information
SectionBlood and blood components- Parenteral > General injections > IV:
Indications -
Plazomicin General information
SectionReserve group antibiotics- Parenteral > General injections > IV: 500 mg per 10 mL
-
Pneumococcal vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Podophyllotoxin General information
SectionDermatological medicines > Medicines affecting skin differentiation and proliferationIndicationsTherapeutic equivalent to podophyllum resin for Anogenital warts Therapeutic equivalent to podophyllum resin for Plantar warts -
Podophyllum resin General information
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Solution: 10 to 25%
Indications -
Poliomyelitis vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Polygeline General information
SectionPlasma substitutes- Parenteral > General injections > IV: 3.5% injectable solution
IndicationsTherapeutic equivalent to dextran 70 for Hypovolaemia -
Polymyxin B (injection) General information
SectionReserve group antibiotics- Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)
-
Potassium chloride General information
SectionSolutions correcting water, electrolyte and acid-base disturbances > Oral- Oral > Liquid: powder for solution
IndicationsSectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL)
Indications -
Potassium ferric hexacyanoferrate (Prussian blue) General information
SectionAntidotes and other substances used in poisonings > Specific- Oral > Solid: Powder for oral administration
-
Potassium iodide General information
SectionAntifungal medicines- Local > Topical > Solution: Saturated solution
IndicationsSectionThyroid hormones and antithyroid medicines- Oral > Solid: 60 mg
Indications -
Potassium permanganate General information
SectionDermatological medicines > Anti-infective medicines- Local > Topical > Solution: aqueous solution: 1:10 000
-
Povidone iodine General information
SectionAntiseptics- Local > Topical > Solution: 10% (equivalent to 1% available iodine)
Indications -
Pravastatin General information
SectionLipid-lowering agentsIndicationsTherapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis -
Praziquantel General information
SectionAntischistosomals and other antitrematode medicines- Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
IndicationsSectionIntestinal anthelminthics- Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
SectionCysticidal medicines- Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg
Indications -
Precipitated sulfur General information
SectionDermatological medicines > Scabicides and pediculicides- Local > Topical > Ointment:
IndicationsTherapeutic equivalent to benzyl benzoate for Pthiriasis Therapeutic equivalent to benzyl benzoate for Pediculosis corporis Therapeutic equivalent to benzyl benzoate for Pediculosis capitis Therapeutic equivalent to benzyl benzoate for Scabies -
Prednisolone General information
SectionAnti-inflammatory medicines- Local > Rectal > Retention enema:
- Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)
IndicationsTherapeutic equivalent to hydrocortisone for Crohn disease site Crohn disease site Ulcerative colitisSectionHormones and antihormones- Oral > Solid: 5 mg; 25 mg
- Oral > Liquid: 5 mg per mL
IndicationsPlasma cell myeloma Follicular lymphoma Lymphoid leukaemia, not elsewhere classified Malignant neoplasms of prostate Chronic lymphocytic leukaemia or small lymphocytic lymphoma Hodgkin lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosisSectionAntiallergics and medicines used in anaphylaxis- Oral > Liquid: 5 mg per mL
- Oral > Solid: 5 mg; 25 mg
SectionOphthalmological preparations > Anti-inflammatory agents- Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)
Indications -
Prednisone General information
SectionHormones and antihormonesIndicationsTherapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Follicular lymphoma Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone for Hodgkin lymphoma Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphomas Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone for Langerhans cell histiocytosisSectionAntiallergics and medicines used in anaphylaxisIndicationsTherapeutic equivalent to prednisolone for Allergic or hypersensitivity conditions of unspecified type -
Pretomanid General information
SectionAntituberculosis medicines- Oral > Solid > tablet: 200 mg
Indications -
Primaquine General information
SectionAntimalarial medicines > For curative treatment- Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)
-
Procaine benzylpenicillin General information
SectionAccess group antibiotics- Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection
-
Procarbazine General information
SectionCytotoxic medicines- Oral > Solid > capsule: 50 mg (as hydrochloride)
Indications -
Progesterone vaginal ring General information
SectionIntravaginal contraceptives- Local > Vaginal > vaginal ring: 2.074 g micronized progesterone
-
Proguanil General information
SectionAntimalarial medicines > For chemoprevention- Oral > Solid: 100 mg tablet (hydrochloride)
Indications -
Propanol General information
SectionAntisepticsIndicationsTherapeutic equivalent to ethanol for Denatured alcohol -
Propofol General information
SectionGeneral anaesthetics and oxygen > Injectable medicines- Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL
Indications -
Propranolol General information
SectionAntimigraine medicines > For prophylaxis- Oral > Solid: 40 mg tablet (hydrochloride); 20 mg tablet (hydrochloride)
Indications -
Propylthiouracil General information
SectionThyroid hormones and antithyroid medicines- Oral > Solid: 50 mg
Indications -
Prostaglandin E1 General information
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 0.5 mg per mL in alcohol
-
Prostaglandin E2 General information
SectionMedicines administered to the neonate [c]- Parenteral > General injections > IV: 1 mg per mL
IndicationsTherapeutic equivalent to prostaglandin E1 for Other specified congenital anomaly of great arteries including arterial duct -
Protamine sulfate General information
SectionMedicines affecting coagulation- Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule
-
Protionamide General information
SectionAntituberculosis medicinesIndicationsTherapeutic equivalent to ethionamide for Multi-drug resistant Mycobacterium tuberculosis -
Pyrantel General information
SectionIntestinal anthelminthics- Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)
Indications -
Pyrazinamide General information
SectionAntituberculosis medicines- Oral > Solid > dispersible tablet: 150 mg
- Oral > Solid > tablet: 400 mg; 500 mg
Indications -
Pyridostigmine General information
SectionMuscle relaxants (peripherally-acting) and cholinesterase inhibitors- Parenteral > General injections > IV: 1 mg in 1 mL ampoule (pyridostigmine bromide)
- Oral > Solid: 60 mg (pyridostigmine bromide)
Indications -
Pyridoxine General information
SectionVitamins and minerals- Oral > Solid: 25 mg (hydrochloride)
-
Pyrimethamine General information
SectionAntipneumocystosis and antitoxoplasmosis medicines- Oral > Solid: 25 mg
Indications -
Quetiapine General information
SectionMedicines for psychotic disordersIndicationsTherapeutic equivalent to risperidone for Schizophrenia or other primary psychotic disordersSectionMedicines for bipolar disorders- Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release)
Indications -
Quinine General information
SectionAntimalarial medicines > For curative treatment- Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride)
- Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)
Indications -
Rabies vaccine General information
SectionRecommendations for some high-risk populations- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Raltegravir General information
SectionAntiretrovirals > Integrase inhibitors- Oral > Liquid: 100 mg granules for oral suspension
- Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)
-
Ranitidine General information
SectionAntiulcer medicines- Oral > Liquid: 75 mg per 5 mL (as hydrochloride)
- Oral > Solid: 150 mg (as hydrochloride)
- Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)
-
Rasburicase General information
SectionSupportive medicines- Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution
Indications -
Ravidasvir General information
SectionMedicines for hepatitis C > Pangenotypic direct-acting antiviral combinations- Oral > Solid > tablet: 200 mg
Indications -
Ready to use therapeutic food General information
SectionTherapeutic foods- Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines.
-
Realgar-indigo naturalis formulation General information
SectionCytotoxic medicines- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
-
Red blood cells General information
SectionBlood and blood components- Parenteral > General injections > IV:
Indications -
Resin-based composite (high-viscosity) General information
SectionDental medicines and preparations- Local > Topical > Other: Single-use capsule or multi-use syringe
Indications -
Resin-based composite (low-viscosity) General information
SectionDental medicines and preparations- Local > Topical > Other: Single-use applicator or multi-use bottle
Indications -
Retinol General information
SectionVitamins and minerals- Parenteral > General injections > IM: 100000 IU in 2 mL ampoule (as palmitate) water-miscible injection
- Oral > Liquid: 100000 IU per mL (as palmitate) oral oily solution in multidose dispenser
- Oral > Solid: 10000 IU (as palmitate) sugar-coated tablet; 200000 IU (as palmitate) capsule; 50000 IU (as palmitate) capsule; 100000 IU (as palmitate) capsule
Indications -
Ribavirin General information
SectionOther antivirals- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg
SectionMedicines for hepatitis C > Other antivirals for hepatitis C- Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
- Oral > Solid: 200 mg; 400 mg; 600 mg
Indications -
Riboflavin General information
SectionVitamins and minerals- Oral > Solid: 5 mg
Indications -
Rifabutin General information
SectionAntituberculosis medicines- Oral > Solid: 150 mg
Indications -
Rifampicin General information
SectionAntituberculosis medicines- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg
IndicationsSectionAntileprosy medicines- Oral > Liquid: 20 mg per mL
- Oral > Solid: 150 mg; 300 mg
Indications -
Rifapentine General information
SectionAntituberculosis medicines- Oral > Solid > tablet: 150 mg; 300 mg
Indications -
Risperidone General information
SectionMedicines for psychotic disorders- Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg
- Parenteral > General injections > IM:
IndicationsSchizophrenia or other primary psychotic disorders Therapeutic equivalent to paliperidone for Schizophrenia or other primary psychotic disorders -
Ritonavir General information
SectionAntiretrovirals > Protease inhibitors- Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)
-
Rituximab General information
SectionTargeted therapies- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
SectionMedicines for multiple sclerosis- Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial
Indications -
Rivaroxaban General information
SectionMedicines affecting coagulationIndicationsTherapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation -
Rotavirus vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
-
Rubella vaccine General information
SectionRecommendations for all immunization programmes- All vaccines should comply with the WHO requirements for biological substances.
Indications -
Salbutamol General information
SectionAntiasthmatic and medicines for chronic obstructive pulmonary disease- Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate)
- Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate); 100 µg per dose (as sulfate) metered-dose inhaler
- Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers
Indications -
Salicylic acid General information
SectionDermatological medicines > Medicines affecting skin differentiation and proliferation- Local > Topical > Solution: 5%
-
Selenium sulfide General information
SectionDermatological medicines > Antifungal medicines- Local > Topical > Suspension: 2% detergent-based
Indications -
Senna General information
SectionMedicines for other common symptoms in palliative care- Oral > Liquid: 7.5 mg per 5 mL oral liquid
IndicationsSectionLaxatives- Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)
Indications -
Sevoflurane General information
SectionGeneral anaesthetics and oxygen > Inhalational medicines- Respiratory > Inhalation > liquid:
Indications -
Silver diamine fluoride General information
SectionDental medicines and preparations- Local > Dental > Solution: 38% w/v
Indications -
Silver sulfadiazine General information
SectionDermatological medicines > Anti-infective medicines- Local > Topical > Cream: 1%
Indications -
Simvastatin General information
SectionLipid-lowering agents- Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg
Indications -
Sodium calcium edetate General information
SectionAntidotes and other substances used in poisonings > Specific- Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule
-
Sodium chloride General information
SectionSolutions correcting water, electrolyte and acid-base disturbances > Parenteral- Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na+ 154 mmol/L and Cl- 154 mmol/L)
-
Sodium hydrogen carbonate General information
SectionSolutions